Movement Alert|Xenon Pharmaceuticals Rises 7.25% in Regular Trading, Trading at $68.07

Market Focus
07/09

On July 8, Xenon Pharmaceuticals rose 7.25% in regular trading, trading at $68.07 USD/share, with Turnover of $124 million.

Within the Biotechnology sector where Xenon Pharmaceuticals belongs, individual stocks showed mixed performance. Among major sector constituents, Amgen up 0.24%, AbbVie down 0.15%, Gilead Sciences down 0.33%, Vertex Pharmaceuticals down 2.98%, Moderna down 6.35%.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on neuroscience, developing therapeutics for neurological disorders. Its pipeline includes Azetukalner (XEN1101), a Kv7 potassium channel opener for epilepsy treatment, for which the company plans to submit a new drug application to the FDA in Q3.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10